Bioxytran, Inc.
BIXT
$0.07
$0.00-1.94%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -41.57% | -58.37% | -45.48% | -20.48% | -23.15% |
| Depreciation & Amortization | 30.68% | -3.30% | -20.41% | -4.82% | 62.96% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.00% | -53.37% | -48.82% | -41.47% | -23.31% |
| Operating Income | 37.00% | 53.37% | 48.82% | 41.47% | 23.31% |
| Income Before Tax | 20.97% | 35.32% | 30.87% | 52.07% | 37.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.97% | 35.32% | 30.87% | 52.07% | 37.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -62.11% | -80.97% | -81.19% | -70.54% | -70.65% |
| Net Income | 20.42% | 34.38% | 30.01% | 51.69% | 36.43% |
| EBIT | 37.00% | 53.37% | 48.82% | 41.47% | 23.31% |
| EBITDA | 37.21% | 53.50% | 48.89% | 41.56% | 23.44% |
| EPS Basic | -36.05% | -4.48% | 8.05% | 52.44% | 46.75% |
| Normalized Basic EPS | -55.65% | -21.92% | -5.18% | 31.68% | 41.92% |
| EPS Diluted | -36.05% | -4.48% | 8.05% | 52.44% | 46.75% |
| Normalized Diluted EPS | -55.65% | -21.92% | -5.18% | 31.68% | 41.92% |
| Average Basic Shares Outstanding | -41.43% | -36.38% | -15.88% | 4.30% | 19.91% |
| Average Diluted Shares Outstanding | -41.43% | -36.38% | -15.88% | 4.30% | 19.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |